News & Press

Filter by year:

GeNeuro Reports 2018 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 1, 2019 –  GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis (MS) and Type-1 Diabetes (T1D), today reported its full-year results for the year ended December 31, 2018 and provided a corporate update.

GeNeuro’s ANGEL-MS Phase 2b extension study confirms and extends the neuroprotective effects of temelimab in MS

Geneva, Switzerland, 12 March 2019 – 07:00am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), type-1 diabetes (T1D) and amyotrophic lateral sclerosis (ALS), today announced positive results from the ANGEL-MS study of its lead product, temelimab in MS. Temelimab is a humanized, monoclonal antibody designed to neutralize pHERV-W, a pathogenic protein thought to be a causal factor in the development of multiple sclerosis.

GeNeuro: Cash position at 31 December 2018 and Business Review

Geneva, Switzerland, 29 January 2019 – 6:00pm CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes, announced its cash position at 31 December 2018 and provides an updated review of its clinical developments.

La Web TV à la rencontre des dirigeants au Biomed Event 2019

Interview diffusée sur la Web TV : www.labourseetlavie.com

GeNeuro Announces Positive Results from Temelimab (GNbAC1) Phase 1 High-dose Clinical Trial

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes, today announced positive safety and tolerability results from a Phase 1 study assessing the administration of high doses of temelimab (GNbAC1) to treat MS and other auto-immune diseases.

 

 


Start Page      Previous Page      Results 11-15 of 15